Benzinga | Aug 25, 2020 06:33AM EDT

Raymond James Initiates Coverage On Sarepta Therapeutics with Outperform Rating, Announces Price Target of $200

Raymond James analyst Danielle Brill initiates coverage on Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform rating and announces Price Target of $200.